

Anil Vasudevan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2396294/publications.pdf>

Version: 2024-02-01

66
papers

2,147
citations

159585

30
h-index

233421

45
g-index

72
all docs

72
docs citations

72
times ranked

2391
citing authors

#	ARTICLE	IF	CITATIONS
1	Microwave-Assisted C-H Bond Activation: A Rapid Entry into Functionalized Heterocycles. <i>Organic Letters</i> , 2003, 5, 2131-2134.	4.6	118
2	2,4-Diamino-5-deaza-6-Substituted Pyrido[2,3-d]pyrimidine Antifolates as Potent and Selective Nonclassical Inhibitors of Dihydrofolate Reductases ^{1,2} . <i>Journal of Medicinal Chemistry</i> , 1996, 39, 1438-1446.	6.4	116
3	2-Aryl-5-carboxytetrazole as a New Photoaffinity Label for Drug Target Identification. <i>Journal of the American Chemical Society</i> , 2016, 138, 14609-14615.	13.7	100
4	Identification of 2-(4-Benzyloxyphenyl)-N-[1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-6-yl]acetamide, an Orally Efficacious Melanin-Concentrating Hormone Receptor 1 Antagonist for the Treatment of Obesity. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 1318-1321.	6.4	91
5	Potent, Highly Selective, and Non-Thiol Inhibitors of Protein Geranylgeranyltransferase-I. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 1333-1340.	6.4	79
6	Design strategies to address kinetics of drug binding and residence time. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 2019-2027.	2.2	69
7	Structure-Based Design and Synthesis of Lipophilic 2,4-Diamino-6-Substituted Quinazolines and Their Evaluation as Inhibitors of Dihydrofolate Reductases and Potential Antitumor Agents ¹ . <i>Journal of Medicinal Chemistry</i> , 1998, 41, 3426-3434.	6.4	64
8	Emerging technologies for metabolite generation and structural diversification. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 5471-5483.	2.2	61
9	6-Substituted 2,4-Diamino-5-methylpyrido[2,3-d]pyrimidines as Inhibitors of Dihydrofolate Reductases from <i>Pneumocystis carinii</i> and <i>Toxoplasma gondii</i> and as Antitumor Agents. <i>Journal of Medicinal Chemistry</i> , 1995, 38, 1778-1785.	6.4	60
10	LOPHTOR: a convenient flow-based photochemical reactor. <i>Tetrahedron Letters</i> , 2010, 51, 4007-4009.	1.4	60
11	High-Throughput Reaction Screening with Nanomoles of Solid Reagents Coated on Glass Beads. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 7987-7991.	13.8	60
12	Discovery and Optimization of Anthranilic Acid Sulfonamides as Inhibitors of Methionine Aminopeptidase-2: A Structural Basis for the Reduction of Albumin Binding. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 3832-3849.	6.4	57
13	A post aza Baylis-Hillman/Heck coupling approach towards the synthesis of constrained scaffolds. <i>Tetrahedron Letters</i> , 2006, 47, 8591-8593.	1.4	57
14	Integrated Platform for Expedited Synthesis-Purification-Testing of Small Molecule Libraries. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 461-465.	2.8	57
15	Heterocyclic ketones as inhibitors of histone deacetylase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 3909-3913.	2.2	55
16	Emerging Approaches for the Identification of Protein Targets of Small Molecules - A Practitioners' Perspective. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8504-8535.	6.4	55
17	Discovery and Characterization of Aminopiperidinecoumarin Melanin Concentrating Hormone Receptor 1 Antagonists. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 5888-5891.	6.4	50
18	Lack of efficacy of melanin-concentrating hormone-1 receptor antagonists in models of depression and anxiety. <i>European Journal of Pharmacology</i> , 2006, 540, 115-120.	3.5	49

#	ARTICLE	IF	CITATIONS
19	Conformationally Restricted Analogues of Trimethoprim: 2,6-Diamino-8-substituted Purines as Potential Dihydrofolate Reductase Inhibitors from <i>Pneumocystis carinii</i> and <i>Toxoplasma gondii</i> . <i>Journal of Medicinal Chemistry</i> , 1997, 40, 3032-3039.	6.4	47
20	Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1998, 275, L55-L63.	2.9	47
21	Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 3574-3577.	2.2	47
22	Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 3077-3079.	2.2	46
23	Selective inhibition of type-I geranylgeranyltransferase in vitro and in whole cells by CAAL peptidomimetics. <i>Bioorganic and Medicinal Chemistry</i> , 1998, 6, 293-299.	3.0	42
24	Neutral, Metal-free Hydration of Alkynes Using Microwave Irradiation in Superheated Water. <i>Synlett</i> , 2004, 2004, 631-634.	1.8	42
25	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 2. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 4879-4882.	2.2	37
26	Aminopiperidine indazoles as orally efficacious melanin concentrating hormone receptor-1 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 5293-5297.	2.2	35
27	Novel Modes of Inhibition of Wild-Type Isocitrate Dehydrogenase 1 (IDH1): Direct Covalent Modification of His315. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 6647-6657.	6.4	34
28	Synthesis of Diazepinones via Intramolecular Transamidation. <i>Organic Letters</i> , 2004, 6, 3361-3364.	4.6	33
29	Screening for Cardiovascular Safety: A Structure-Activity Approach for Guiding Lead Selection of Melanin Concentrating Hormone Receptor 1 Antagonists. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 2339-2352.	6.4	33
30	Standardization Protocols and Optimized Precursor Sets for the Efficient Application of Automated Parallel Synthesis to Lead Optimization: A Mitsunobu Example. <i>ACS Combinatorial Science</i> , 2002, 4, 442-456.	3.3	32
31	Covalent binders in drug discovery. <i>Progress in Medicinal Chemistry</i> , 2019, 58, 1-62.	10.4	32
32	What is in Our Kit? An Analysis of Building Blocks Used in Medicinal Chemistry Parallel Libraries. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 17115-17122.	6.4	32
33	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 4873-4877.	2.2	29
34	Synthesis and Biological Evaluation of Nonclassical 2,4-Diamino-5-methylpyrido[2,3-d]pyrimidines with Novel Side Chain Substituents as Potential Inhibitors of Dihydrofolate Reductases. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 479-485.	6.4	27
35	Efficient Pd-catalyzed synthesis of 2-arylaminopyrimidines via microwave irradiation. <i>Tetrahedron Letters</i> , 2006, 47, 4881-4884.	1.4	24
36	Synthesis and evaluation of potent pyrrolidine H3 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 3055-3058.	2.2	23

#	ARTICLE	IF	CITATIONS
37	Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 11074-11100.	6.4	23
38	Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 3. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 4883-4886.	2.2	22
39	A post-Ugi carbonylation/intramolecular amidation approach toward the synthesis of macrolactams. <i>Tetrahedron Letters</i> , 2005, 46, 1697-1701.	1.4	20
40	Identification of aminopiperidine benzamides as MCHr1 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 3412-3416.	2.2	18
41	Identification of ortho-amino benzamides and nicotinamides as MCHr1 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 4174-4179.	2.2	18
42	Cell-Surface Receptorâ€“Ligand Interaction Analysis with Homogeneous Time-Resolved FRET and Metabolic Glycan Engineering: Application to Transmembrane and GPI-Anchored Receptors. <i>Journal of the American Chemical Society</i> , 2017, 139, 16822-16829.	13.7	18
43	De Novo Design, Synthesis, and Biological Evaluation of 3,4-Disubstituted Pyrrolidine Sulfonamides as Potent and Selective Glycine Transporter 1 Competitive Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 7486-7502.	6.4	17
44	Development of Orally Efficacious Allosteric Inhibitors of TNFÎ± via Fragment-Based Drug Design. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 417-429.	6.4	17
45	SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 3317-3325.	2.2	14
46	Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 7615-7622.	2.2	12
47	Discovery of Novel Aminotetralines and Aminochromanes as Selective and Competitive Glycine Transporter 1 (GlyT1) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 7503-7524.	6.4	12
48	Are We There Yet? Applying Thermodynamic and Kinetic Profiling on Embryonic Ectoderm Development (EED) Hit-to-Lead Program. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 8321-8335.	6.4	11
49	Highâ€“Throughput Reaction Screening with Nanomoles of Solid Reagents Coated on Glass Beads. <i>Angewandte Chemie</i> , 2019, 131, 8071-8075.	2.0	11
50	Lead Optimization Strategies and Tactics Applied to the Discovery of Melanin Concentrating Hormone Receptor 1 Antagonists. <i>Current Topics in Medicinal Chemistry</i> , 2007, 7, 1471-1488.	2.1	10
51	Development of inverse electron demand Dielsâ€“Alder ligation and TR-FRET assays for the determination of ligandâ€“protein target occupancy in live cells. <i>MedChemComm</i> , 2017, 8, 789-795.	3.4	8
52	Design of Aminobenzothiazole Inhibitors of Rho Kinases 1 and 2 by Using Protein Kinaseâ€“A as a Structure Surrogate. <i>ChemBioChem</i> , 2018, 19, 613-621.	2.6	6
53	Glycanâ€“Mediated, Ligandâ€“Controlled Click Chemistry for Drugâ€“Target Identification. <i>ChemBioChem</i> , 2016, 17, 150-154.	2.6	4
54	Controlling cellular distribution of drugs with permeability modifying moieties. <i>MedChemComm</i> , 2019, 10, 974-984.	3.4	4

#	ARTICLE	IF	CITATIONS
55	Current Innovations in Medicinal Chemistry and Chemical Biology. ACS Medicinal Chemistry Letters, 2018, 9, 513-514.	2.8	2
56	Standardization Protocols and Optimized Precursor Sets for the Efficient Application of Automated Parallel Synthesis to Lead Optimization: A Mitsunobu Example.. ChemInform, 2003, 34, no.	0.0	0
57	Synthesis and Evaluation of Potent Pyrrolidine H3 Antagonists.. ChemInform, 2003, 34, no.	0.0	0
58	Aminoalkoxybiphenylnitriles as Histamine-3 Receptor Ligands.. ChemInform, 2003, 34, no.	0.0	0
59	Microwave-Assisted C-H Bond Activation: A Rapid Entry into Functionalized Heterocycles.. ChemInform, 2003, 34, no.	0.0	0
60	Heterocyclic Ketones as Inhibitors of Histone Deacetylase.. ChemInform, 2004, 35, no.	0.0	0
61	Neutral, Metal-Free Hydration of Alkynes Using Microwave Irradiation in Superheated Water.. ChemInform, 2004, 35, no.	0.0	0
62	Synthesis of Diazepinones via Intramolecular Transamidation.. ChemInform, 2005, 36, no.	0.0	0
63	Synthesis and Evaluation of 2-Amino-8-alkoxy Quinolines as MCHR1 Antagonists. Part 2.. ChemInform, 2005, 36, no.	0.0	0
64	A Post-Ugi Carbonylation/Intramolecular Amidation Approach Toward the Synthesis of Macrolactams.. ChemInform, 2005, 36, no.	0.0	0
65	Identification of Aminopiperidine Benzamides as MCHR1 Antagonists.. ChemInform, 2005, 36, no.	0.0	0
66	A Dual-Purpose Bromocoumarin Tag Enables Deep Profiling of the Cellular Cysteineome. Proteomics, 2019, 19, 1800433.	2.2	0